Zobrazení zdroje stránky Stokesxu7900

Melanomacrophagic centers (MMCs) were studied in the liver of zebrafish using transmission electron microscope (TEM). The MMCs were located in the space of Disse (SD), and their pseudopodia protruded into the lumen of sinusoids. The degree of extension of body structure of MMCs in the SD was determined by the size of the phagocytosed content. An irregular or amoeboid nucleus was present. Vacuoles were occasionally present, both, in endothelium and MMCs. The cytoplasm of MMCs showed several engulfed structures. The most common structure was the presence of mitochondria of small to giant size and distorted shape with inconspicuous cristae. The product of mitochondrial degeneration accompanied by lysosomes contributed to the formation of lipofuscins. Besides, changes were also observed in rough endoplasmic reticulum (rER), the Golgi complex, and lysosomes. [https://www.selleckchem.com/products/Cediranib.html AZD2171] Occasionally, small to large fragments of the erythrocytes were found in the cytoplasm of MMCs. The rER encompassed the mitochondria and lipid droplets forming a membrane-like structure. Golgi complex were dilated. Lysosomes fused with such membrane-bound structures contributed to the formation of the lipofuscin. The results provide evidence of the role of liver-resident MMCs of zebrafish in phagocytosis of damaged organelles, clearance of the worn-out erythrocytes, and lipofuscin formation.Diffusion-tensor imaging (DTI) has been used in the assessment of the central nervous system for the past 3 decades and has demonstrated great utility for the functional assessment of normal and pathologic white matter. Recent technical advances have permitted the expansion of DTI applications to the spinal cord. MRI of the spinal cord has traditionally been limited to conventional sequences, which provide information regarding changes in the anatomic shape of a structure or its signal intensity, suggesting the presence of a pathologic entity. However, conventional MRI lacks the ability to provide pathophysiologic information. DTI of the spinal cord can deliver pathophysiologic information on a molecular basis and thereby has several adjunctive uses. These advantages have yet to be fully evaluated, and therefore spinal DTI lacks widespread adoption. The barriers to implementation include a lack of understanding of the underlying physics principles needed to make necessary technical adjustments to obtain diagnostic images, as well as the need for standardization of protocols and postprocessing methods. The authors provide a comprehensive review of the physics of spinal cord DTI and the technical adjustments required to obtain diagnostic images and describe tips and tricks for accurate postprocessing. The primary clinical applications for spinal cord DTI are reviewed. Online supplemental material is available for this article. ©RSNA, 2020 See discussion on this article by Smith.Fetal hepatomegaly is associated with significant fetal morbidity and mortality. However, hepatomegaly might be overlooked when numerous other fetal anomalies are present, or it might not be noticed when it is an isolated entity. As the largest solid organ in the abdomen, the liver can be seen well with US or MRI, and the normal imaging characteristics are well described. The length of the fetal liver, which can be used to identify hepatomegaly, can be determined by measuring the liver from the diaphragm to the tip of the right lobe in the sagittal plane. Fetal hepatomegaly is seen with infection, transient abnormal myelopoiesis, liver storage and deposition diseases, some syndromes, large liver tumors, biliary atresia, and anemia. Some of these diagnoses are treatable during the fetal period. Attention to the associated findings and specific hepatic and nonhepatic imaging characteristics can help facilitate more accurate diagnoses and appropriate patient counseling.©RSNA, 2020.US is a powerful and nearly ubiquitous tool in the practice of interventional radiology. Use of contrast-enhanced US (CEUS) has gained traction in diagnostic imaging given the recent approval by the U.S. Food and Drug Administration (FDA) of microbubble contrast agents for use in the liver, such as sulfur hexafluoride lipid-type A microspheres. Adoption of CEUS by interventional radiologists can enhance not only procedure guidance but also preprocedure patient evaluation and assessment of treatment response across a wide spectrum of oncologic, vascular, and nonvascular procedures. In addition, the unique physical properties of microbubble contrast agents make them amenable as therapeutic vehicles in themselves, which can lay a foundation for future therapeutic innovations in the field in drug delivery, thrombolysis, and vascular flow augmentation. The purpose of this article is to provide an introduction to and overview of CEUS aimed at the interventional radiologist, highlighting its role before, during, and after frequently practiced oncologic and vascular interventions such as biopsy, ablation, transarterial chemoembolization, detection and control of hemorrhage, evaluation of transjugular intrahepatic portosystemic shunts (TIPS), detection of aortic endograft endoleak, thrombus detection and evaluation, evaluation of vascular malformations, lymphangiography, and percutaneous drain placement. Basic physical principles of CEUS, injection and scanning protocols, and logistics for practice implementation are also discussed. Early adoption of CEUS by the interventional radiology community will ensure rapid innovation of the field and development of future novel procedures. Online supplemental material is available for this article. ©RSNA, 2020.A nonmass finding at US has been described as a discrete identifiable area of altered echotexture compared with that of the surrounding breast tissue that does not conform to a mass shape. Recognizing nonmass findings is important because breast cancer can manifest as such lesions, and US correlate findings for mammographic and breast MRI abnormalities may manifest as nonmass findings. The term nonmass finding is not part of the current Breast Imaging Reporting and Data System US terminology, and no standardized approach to classify and evaluate nonmass findings at US currently exists, despite the various classification systems proposed in the literature. There is also considerable overlap between the sonographic features of benign and malignant causes of nonmass findings. These limitations cause diagnostic difficulty in evaluating clinical significance and recommending appropriate management. The authors review the definitions and classification systems of US nonmass findings proposed in the literature and illustrate the sonographic features of nonmass findings to help radiologists identify them at US.